Newronika Company

Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normal daily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. ​ Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies.

Total Funding: €10.1M
Headquarters: United Kingdom
Funding Status: Early Stage Venture
Employee Number: 11-50
Estimated Revenue: Less than $1M
Last Funding Type: Series A
Technology: Neuroscience Research
Investor Type: For Profit
Investors Number: 6
Founded Date: 2017-09-01
Industry: NeuroTech